XERS XP-8121 targets $1–3B peak sales by 2030 launch
XERS said XP-8121, a once-weekly injectable levothyroxine, aims for $1–3B peak sales, targeting 3–5 million hypothyroid patients inadequately controlled on oral therapy. An FDA-aligned pivotal trial is set to support approval and launch by 2030.